TY - JOUR
T1 - Multiparameter immunohistochemistry analysis of HIV DNA, RNA and immune checkpoints in lymph node tissue
AU - Richardson, Zuwena A.
AU - Deleage, Claire
AU - Tutuka, Candani S.A.
AU - Walkiewicz, Marzena
AU - Del Río-Estrada, Perla M.
AU - Pascoe, Rachel D.
AU - Evans, Vanessa A.
AU - Reyesteran, Gustavo
AU - Gonzales, Michael
AU - Roberts-Thomson, Samuel
AU - González-Navarro, Mauricio
AU - Torres-Ruiz, Fernanda
AU - Estes, Jacob D.
AU - Lewin, Sharon R.
AU - Cameron, Paul U.
N1 - Funding Information:
We acknowledge the participants who donated their LNs for this study, Dr. Mauricio González-Navarro and Dr. Fernanda Torres-Ruiz for performing the LN biopsies (Centro de Investigación en Enfermdades Infecciosas, Mexico city, Mexico). We thank Caroline Tumpach and Michael Roche for providing us with cells (RMIT, Melbourne Australia and Peter Doherty Institute, Melbourne Australia), Dr. Andreas Behren (Olivia Newton John Cancer Institute) for using his lab and imaging facility, Metta Jana, Rejhan Idriza and Cameron Skinner for the analysis and imaging facility (Petermac, Melbourne, Australia), Dr. Byron Martina for proof-reading (Erasmus MC, Rotterdam, The Netherlands), T. Luka, C. Li for flow cytometric cell sorting (University of Melbourne Flow Cytometry Facility, Melbourne, Australia). This work was funded by grants to Sharon Lewin from National Institutes of Health Delaney AIDS Research Enterprise to Find a Cure Collaboratory (Grant UM1AI126611-01 ). JD Este was funded from the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases and National Institute of Allergy and Infectious Diseases grants R01 DK119945 (JDE) and R01 AI143411-01A1 (JDE). SRL is an NHMRC Practitioner Fellow
Funding Information:
We acknowledge the participants who donated their LNs for this study, Dr. Mauricio Gonz?lez-Navarro and Dr. Fernanda Torres-Ruiz for performing the LN biopsies (Centro de Investigaci?n en Enfermdades Infecciosas, Mexico city, Mexico). We thank Caroline Tumpach and Michael Roche for providing us with cells (RMIT, Melbourne Australia and Peter Doherty Institute, Melbourne Australia), Dr. Andreas Behren (Olivia Newton John Cancer Institute) for using his lab and imaging facility, Metta Jana, Rejhan Idriza and Cameron Skinner for the analysis and imaging facility (Petermac, Melbourne, Australia), Dr. Byron Martina for proof-reading (Erasmus MC, Rotterdam, The Netherlands), T. Luka, C. Li for flow cytometric cell sorting (University of Melbourne Flow Cytometry Facility, Melbourne, Australia). This work was funded by grants to Sharon Lewin from National Institutes of Health Delaney AIDS Research Enterprise to Find a Cure Collaboratory (Grant UM1AI126611-01). JD Este was funded from the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases and National Institute of Allergy and Infectious Diseases grants R01 DK119945 (JDE) and R01 AI143411-01A1 (JDE). SRL is an NHMRC Practitioner Fellow
Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2022/2
Y1 - 2022/2
N2 - The main barrier to a cure for HIV is the persistence of long-lived and proliferating latently infected CD4+ T-cells despite antiretroviral therapy (ART). Latency is well characterized in multiple CD4+ T-cell subsets, however, the contribution of regulatory T-cells (Tregs) expressing FoxP3 as well as immune checkpoints (ICs) PD-1 and CTLA-4 as targets for productive and latent HIV infection in people living with HIV on suppressive ART is less well defined. We used multiplex detection of HIV DNA and RNA with immunohistochemistry (mIHC) on formalin-fixed paraffin embedded (FFPE) cells to simultaneously detect HIV RNA and DNA and cellular markers. HIV DNA and RNA were detected by in situ hybridization (ISH) (RNA/DNAscope) and IHC was used to detect cellular markers (CD4, PD-1, FoxP3, and CTLA-4) by incorporating the tyramide system amplification (TSA) system. We evaluated latently infected cell lines, a primary cell model of HIV latency and excisional lymph node (LN) biopsies collected from people living with HIV (PLWH) on and off ART. We clearly detected infected cells that coexpressed HIV RNA and DNA (active replication) and DNA only (latently infected cells) in combination with IHC markers in the in vitro infection model as well as LN tissue from PLWH both on and off ART. Combining ISH targeting HIV RNA and DNA with IHC provides a platform to detect and quantify HIV persistence within cells identified by multiple markers in tissue samples from PLWH on ART or to study HIV latency.
AB - The main barrier to a cure for HIV is the persistence of long-lived and proliferating latently infected CD4+ T-cells despite antiretroviral therapy (ART). Latency is well characterized in multiple CD4+ T-cell subsets, however, the contribution of regulatory T-cells (Tregs) expressing FoxP3 as well as immune checkpoints (ICs) PD-1 and CTLA-4 as targets for productive and latent HIV infection in people living with HIV on suppressive ART is less well defined. We used multiplex detection of HIV DNA and RNA with immunohistochemistry (mIHC) on formalin-fixed paraffin embedded (FFPE) cells to simultaneously detect HIV RNA and DNA and cellular markers. HIV DNA and RNA were detected by in situ hybridization (ISH) (RNA/DNAscope) and IHC was used to detect cellular markers (CD4, PD-1, FoxP3, and CTLA-4) by incorporating the tyramide system amplification (TSA) system. We evaluated latently infected cell lines, a primary cell model of HIV latency and excisional lymph node (LN) biopsies collected from people living with HIV (PLWH) on and off ART. We clearly detected infected cells that coexpressed HIV RNA and DNA (active replication) and DNA only (latently infected cells) in combination with IHC markers in the in vitro infection model as well as LN tissue from PLWH both on and off ART. Combining ISH targeting HIV RNA and DNA with IHC provides a platform to detect and quantify HIV persistence within cells identified by multiple markers in tissue samples from PLWH on ART or to study HIV latency.
KW - HIV latency
KW - Immune checkpoints
KW - Immunohistochemistry
KW - In situ hybridization
KW - Lymph nodes
KW - Microscopy
KW - RNAscope
UR - http://www.scopus.com/inward/record.url?scp=85120997526&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120997526&partnerID=8YFLogxK
U2 - 10.1016/j.jim.2021.113198
DO - 10.1016/j.jim.2021.113198
M3 - Article
C2 - 34863818
AN - SCOPUS:85120997526
SN - 0022-1759
VL - 501
JO - Journal of Immunological Methods
JF - Journal of Immunological Methods
M1 - 113198
ER -